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The LG4 module of the laminin 3 chain (3 LG4), a
component of epithelial-specific laminin-5, has cell at-
tachment activity and binds syndecan (Utani, A., No-
mizu, M., Matsuura, H., Kato, K., Kobayashi, T., Takeda,
U., Aota, S., Nielsen, P. K., and Shinkai, H. (2001) J. Biol.
Chem. 276, 28779–28788). Here, we show that recombi-
nant 3 LG4 and a 19-mer synthetic peptide (A3G756)
within 3 LG4 active for syndecan binding increased the
expression of matrix metalloproteinase-1 (MMP-1) in ke-
ratinocytes and fibroblasts. This induction was inhib-
ited by heparin and required de novo synthesis of pro-
teins. In keratinocytes, A3G756 up-regulated
interleukin (IL)-1 and MMP-1 expression and an IL-1
receptor antagonist thoroughly inhibited A3G756-medi-
ated induction of MMP-1. A3G756 also activated p38 mi-
togen-activated protein kinase (p38 MAPK) and extra-
cellular signal-related kinase (Erk). Studies with
specific inhibitors of MAPKs showed that p38 MAPK
activation was necessary for both IL-1 and MMP-1 in-
duction, but Erk activation was required only for
MMP-1 induction. In fibroblasts, IL-1 receptor antago-
nist did not block A3G756-mediated induction of MMP-1.
These results indicated that induction of MMP-1 by 3
LG4 is mediated through the IL-1 autocrine loop in
keratinocytes but the mechanism of the induction in
fibroblasts is different. Our study suggests that the lami-
nin 3 LG4 module may play an important role in tissue
remodeling by inducing MMP-1 expression during
wound healing.
Laminin is a heterotrimeric glycoprotein specific to the base-
ment membrane and has many biological functions, including
cell adhesion, migration, cell proliferation, differentiation, an-
giogenesis, and tumor invasion (for reviews, see Refs. 1 and 2).
At least 15 laminin isoforms (laminin-1 to -15) have been iden-
tified with 11 genetically distinct chains: 5  chains, 3  chains,
and 3  chains. Three chains assemble into a cross-shaped
heterotrimer () through coiled-coil interaction at the long
arm of the cross (3, 4). Laminin-5 is specific to epithelial cells
and a component of the anchoring filament. Laminin-5 forms a
complex with the hemidesmosome apparatus by interacting
with laminin-6 and -7, collagen VII (5, 6), and fibulin-1 and -2
(7, 8). Laminin-5 consists of the 3, 3, and 2 chains. The 3
chain contains a large globular module (G module)1 at the C
terminus, which consists of a tandem repeat of five homologous
LG modules (LG1–LG5), each module containing about 200
amino acid residues autonomous folding unit (9). The LG sub-
domains of laminin  chains have been shown to bind heparin,
31, 64 integrins, -dystroglycan, and syndecan (Ref. 10; for
review, see Ref. 11) and are implicated as active regions for
various biological functions.
Syndecans, cell surface heparan sulfate proteoglycans, have
been shown to bind the G module of laminin  chains and are
involved in laminin-mediated biological functions. We previ-
ously demonstrated that keratinocytes and fibroblasts bound
LG4 of the 3 G module via syndecans (12). Neurite outgrowth
of PC12 cells was induced by 3 LG4 via syndecans (13). We
also showed that HT1080 cells bound to the C-terminal G
module of the laminin 4 chain through syndecans (14). The
interaction of laminin 1 LG4 and syndecan family or heparan
sulfate proteoglycans was essential for embryonic basement
membrane assembly (15).
Although laminin 3 LG4–5 is processed in the keratinocyte
culture medium (16, 17), the unprocessed laminin 3 chain was
found in a cell layer of the provisional edge of the cell sheet in
cultured keratinocytes. In vivo, the unprocessed 3 chain has
been identified especially in the newly synthesized epidermal
basement membrane in wounds but disappears from the mature
basement membrane (Refs. 18 and 19; for review, see Ref. 20).
Matrix metalloproteinase-1 (MMP-1) is expressed in the ba-
sal keratinocytes at the leading edge of re-epithelization (Refs.
21 and 22; for review, see Ref. 23). At the wound edge, MMP-1
degrades collagen and promotes cell migration and wound clo-
sure. The similar temporal and spatial localization of MMP-1
and unprocessed 3 chain led us to study the relationship
between MMP-1 induction and signaling pathways induced by
the laminin 3 LG4 module. In the present work, we demon-
strated that the laminin 3 LG4 module induced MMP-1 ex-
pression by the activation of MAPK via syndecan receptor.
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EXPERIMENTAL PROCEDURES
Cultured Cells—Human neonatal dermal fibroblasts were obtained
from Asahi Techno Glass Co. (Tokyo, Japan). 293T cells were derived
from 293 cells as temperature-sensitive subclones (24). These cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen),
100 units/ml penicillin, and 50 units/ml streptomycin. Human primary
keratinocytes were purchased from Clonetics (San Diego, CA) and
maintained in keratinocyte-SFM supplemented with epidermal growth
factor and bovine pituitary extracts (Invitrogen). Keratinocytes and
fibroblasts were used at the second through fifth passages in the
experiments.
Reagents—Anti-phospho-p44/42 MAPK (Erk) polyclonal antibody,
anti-phospho-p38 MAPK polyclonal antibody, and anti-phospho-stress-
activated protein kinase/c-Jun N-terminal kinase polyclonal antibody
were purchased from Cell Signaling Technology (Beverly, MA). Poly-
clonal antibody to p38 MAPK was a kind gift from Dr. Sudo (Antibiotics
Laboratory, RIKEN, Saitama, Japan) (25). Anti-Erk2 monoclonal anti-
body was purchased from Upstate Biotechnology, Inc. (Waltham, MA).
Anti-human IL-1 monoclonal antibody (AF-201-NA) was obtained
from R&D Systems (Minneapolis, MN). Anti-human MMP-1 polyclonal
antibody (444209) was from Calbiochem (San Diego, CA). Peroxidase-
conjugated anti-rabbit and anti-mouse IgG antibodies and ECL (Amer-
sham Biosciences, Uppsala, Sweden) were used for Western blotting.
Human syndecan-4 monoclonal antibody (5G9) and human syndecan-2
antibody (L-18) were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Fluorescein isothiocyanate (FITC)-conjugated anti-
mouse IgG antibody and Cy3-conjugated anti-human IgG antibody
were purchased from Jackson ImmunoResearch Laboratories (West
Grove, PA). FITC-conjugated anti-heparan sulfate antibody (10E4) was
obtained from Seikagaku Kogyo (Tokyo, Japan). MAPK inhibitors
SB202190 and PD98059 were from Calbiochem and dissolved in di-
methyl sulfoxide (Me2SO). IL-1 was obtained from Roche Diagnostics
(Indianapolis, IN). Human IL-1 receptor antagonist (IL-1RA, which
traps IL-1) was purchased from R&D Systems. Heparin was from
Seikagaku Kogyo and cycloheximide from Sigma.
Recombinant Proteins—Recombinant 3 LG4 was expressed as a
chimera with a human IgG Fc portion at the C terminus and purified as
previously described with a minor modification (12). Briefly, recombi-
nant proteins were expressed in 293 T cells by the Ca-P transfection kit
(Invitrogen). After 24 h, cells were incubated with Chinese hamster
ovary medium (Invitrogen) for another 2 days, followed by purification
with protein A-Sepharose (Amersham Biosciences).
Synthesis of A3G756—Peptides were manually synthesized by the
Fmoc (N-(9-fluorenyl)methoxycarbonyl)-based solid-phase methods
with a C-terminal amide as previously described (26). Peptides were
purified by reverse phase high performance liquid chromatography
(HPLC) using a Mightysil RP-18 column (Kanto Chemical Co., Inc.,
Tokyo, Japan) with a gradient of water/acetonitrile containing 0.1%
trifluoroacetic acid. Purity and identity were confirmed by HPLC and
by fast atom bombardment mass spectral analysis at the GC-MS &
NMR Laboratory, Graduate School of Agriculture, Hokkaido University
(Hokkaido, Japan). The A3G756 peptide (residues 1411–1429, KNSF-
MALYLSKGRLVFALG) showed syndecan-mediated cell attachment in
a heparin dependent manner as strong as the previously identified
12-mer active peptide (residues 1412–1423, NSFMALYLSKGR) (12).
Peptide S4 (LVAGAFFKRKLLLMNSSGY) was a scrambled peptide of
A3G756, and cell adhesion and inhibition assays demonstrated that S4
had no adhesion activity.
Treatment of Cells—Keratinocytes were seeded at 1.0  105 in 12-
well plastic dishes. After 24 h, early confluent cells were starved for 24 h
in keratinocyte-SFM. Fibroblasts (2.0  105) were seeded in 12-well
dishes, and were settled for several hours until attaching, followed by
24 h of starvation in DMEM containing 0.1% BSA. Then, recombinant
protein, peptides, or cytokine were added in 0.4 ml of fresh medium.
Cells were pretreated with 2 g/ml cycloheximide for 2 h before stim-
ulation. MAPK inhibitors, 30 g/ml SB202190, 20 g/ml PD98059, or
Me2SO only were added 1 h before stimulation.
RT-PCR Analysis of MMP-1—Total RNA was prepared from cells
after 8-h incubation by RNAeasy kit (Qiagen GmbH, Hilden, Germany).
cDNA was synthesized from RNA (2.0 g) with an oligo(dT) primer in a
total volume of 21 l by SPreamplification System (Invitrogen). cDNA
(1 l for IL-1 or 0.1 l for MMP-1 and GAPDH) was subjected to PCR
for amplification. In preliminary experiments, we determined the opti-
mal number of cycles within the linearity of reactions for each PCR
product. The cycle number was 35 cycles for IL-1 and was 25 cycles for
MMP-1 and GAPDH. The primers for PCR are as follows: human
MMP-1 (830–1465 nt, GenBankTM accession no. X54925), forward (5-
CATCCAAGCCATATATGGACG) and backward (5-GCAGTTGAAC-
CAGCTATTAGC); human GAPDH (292–885 nt, GenBankTM J04038),
forward (5-CCCATCACCATCTTCCAG) and backward (5-CCTGCT-
TCACCACCTTCT); human IL-1 (541–1331 nt, GenBankTM M15330),
forward (5-AGCAACAAGTGGTGTTCTCCATG) and backward (5-
CTAGGCTCTTTTACAGACACTGC). Using these primers, PCR was
performed by the Expand High Fidelity PCR System (Roche Diagnos-
tics) at 94 °C for 4 min followed by individual cycles at 94 °C for 30 s,
58 °C for 30 s, and 72 °C for 1 min with an extension step of 7 min at
72 °C at the end of the last cycle. The products were separated on 1.5%
agarose gel. The bands were visualized with ethidium bromide staining.
The intensity of the products was calculated with NIH Image 1.60, and
the values were depicted as the ratio to those of GAPDH.
ELISA—Fibroblasts were treated with reagents in 0.4 ml of DMEM
containing 0.1% BSA. The triplicate conditioned media were collected,
and MMP-1 was measured by the Human Matrix Metalloproteinase 1
ELISA System (Amersham Bioscience) using precoated 96-well immu-
noplates. Absorbance was read at 450 nm with microplate reader. The
MMP-1 level was calculated by standard curve with an internal control
following the protocol from the manufacturer.
Western Blotting—Keratinocytes and fibroblasts were treated as de-
scribed above. Conditioned media were collected. The media were ly-
ophilized and dissolved in 50 l of sample buffer (20% glycerol, 2% SDS,
125 mM Tris-HCl, pH 6.8, 2% mercaptoethanol, and 0.15% bromphenol
blue), and 20 l of sample was subjected to Western blotting. Cells were
washed with ice-cold PBS twice and were lysed on ice by the addition of
40 l of lysis buffer (20 mM Tris-HCl, pH 7.5, 60 mM glycerophosphate,
10 mM EGTA, 10 mM MgCl2, 10 mM NaF, 2 mM dithiothreitol, 1 mM
N3VO4, 1 mM phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, and
1% Nonidet P-40) for 15 min. Cell lysates were cleared by centrifugation
at 20,000  g at 4 °C for 15 min. Aliquot (15 l) was boiled in sample
buffer for 5 min and subjected to 12% SDS-PAGE, and transferred by
electroblotting onto polyvinylidene difluoride transfer membranes (Im-
mobilonTM, Millipore, Bedford, MA). The membranes were blocked with
10% nonfat milk in Tris-buffered saline (150 mM NaCl, 40 mM Tris-HCl,
pH 7.4) plus 0.1% Tween 20, probed with the first antibodies (1:200),
and visualized by the peroxidase-conjugated second antibodies (1:2000–
1:5000) and an ECL system (Amersham Biosciences). Densitometric
analysis was carried out using NIH Image software version 1.60. To
verify the amounts of the samples, membrane was probed with anti-p38
MAPK or anti-Erk2 antibody after stripping.
Syndecan-2 and -4 Overexpression in Mammalian Cells—cDNA of
whole human syndecan-2 (577–1,245 nt, GenBankTM J04621) and
cDNA of whole human syndecan-4 (9–623 nt, GenBankTM X67016)
were amplified using mRNA derived from dermal fibroblasts as de-
scribed previously (12). Briefly, PCR product was subcloned into the
expression vector (27) containing a cytomegalovirus promoter and an
internal ribosome entry site and puromycine-resistant gene (28). Hu-
man primary dermal fibroblasts were transfected by LipofectAMINE
(Invitrogen), and clones producing syndecan-2 and -4 were selected with
0.4 g/ml puromycin (Sigma). Both Western blotting and immuno-
staining with anti-syndecan-4 antibody confirmed selected syndecan-4-
producing clones. The selected syndecan-2-expressing clones were an-
alyzed by Western blotting with anti-syndecan-2 antibody and
immunostaining with FITC-anti-heparan sulfate antibody.
Immunocytochemistry—Fibroblasts on cover glass that overex-
pressed syndecan-2 and -4 were fixed by 4% paraformaldehyde/PBS for
15 min at room temperature and blocked with 5% normal donkey serum
(Chemicon International, Inc., Temecula, CA), 1% BSA (Sigma), 0.05%
Nonidet P-40 (Sigma), PBS for 15 min. Cells were incubated with
recombinant 3 LG4 (10 g/ml) and anti-syndecan-4 monoclonal anti-
body (1:50) at 4 °C overnight, followed by Cy3-conjugated anti-human
IgG antibody (1:200) and FITC-conjugated anti-mouse IgG antibody
(1:200) for 30 min at 37 °C. For syndecan-2 staining, FITC-conjugated
anti-heparan sulfate antibody was used. After washing, pictures were
taken by Nikon fluorescent microscopy.
Molecular Modeling—A model of the 3 LG4–5 structure was gen-
erated using ProMod II version 3.5 (29) with the x-ray derived coordi-
nates of the mouse 2 LG4–5 module pair (Protein Data Bank code
1dyk) (30) as a template, resulting in a final total energy of 3980
kJ/mol. As expected from sequence alignments, the model shows disul-
fide bonds between Cys-1354 and Cys-1617, Cys-1507 and Cys-1530,
and Cys-1682 and Cys-1710.
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RESULTS
Laminin 3 LG4 and A3G756 Induce MMP-1 Expression—
We previously showed that laminin 3 LG4 and peptide
A3G756 within 3 LG4 bind keratinocytes and fibroblasts
through syndecans (12). We hypothesized that this interaction
regulates expression of MMP-1 during wound healing. There-
fore, we examined expression levels of MMP-1 in keratinocyte
and fibroblasts when these cells were incubated with 3 LG4
and A3G756. RT-PCR analysis demonstrated that recombinant
3 LG4 and peptide A3G756 stimulated MMP-1 mRNA expres-
sion in keratinocytes, whereas control peptide S4 (scrambled
A3G756 peptide sequence) did not change MMP-1 mRNA (Fig.
1, A and B). This increase was strongly blocked by the addition
of heparin into the medium (Fig. 1, A and B). The heparin-de-
pendent MMP-1 induction and syndecan binding to the
A3G756 peptide suggest that the induction process is mediated
through syndecans.
Because IL-1 is known to induce MMP-1 expression (31,
32), we next examined whether A3G756 increases IL-1 mRNA
levels. In both keratinocytes and fibroblasts, A3G756 signifi-
cantly increased IL-1 mRNA expression (Fig. 1C). We also
confirmed that IL-1 induced MMP-1 expression in these cell
types, agreeing with previous reports (Fig. 1D). Because a 4-h
incubation with A3G756 was not sufficient to induce MMP-1
gene expression (data not shown), de novo synthesis of some
factors might be necessary in this induction process. Pretreat-
ment of keratinocytes with cycloheximide, an inhibitor of trans-
lation, totally diminished the up-regulation of MMP-1 gene
expression by A3G756 (Fig. 1E). These results indicate that de
novo protein synthesis is required for A3G756-mediated
MMP-1 induction. On the contrary, cycloheximide did not in-
hibit up-regulation of IL-1 gene expression (data not shown),
suggesting that the up-regulation of IL-1 by A3G756 did not
require new synthesis of a factor(s). Thus, IL-1 is a likely
candidate responsible for the synthesis of a new factor involved
in the up-regulation of MMP-1 by A3G756.
IL-1 Receptor Antagonist Blocks MMP-1 Induction by
A3G756 in Keratinocytes but Not in Fibroblasts—To further
investigate the mechanism of IL-1 action, we next examined
the effect of IL-1 receptor antagonist on A3G756-mediated
MMP-1 induction. In keratinocytes, IL-1RA (IL-1 receptor an-
tagonist) at 0.3 g/ml inhibited the increase of MMP-1 gene
expression by A3G756 (Fig. 2A). On the contrary, in fibroblasts
A3G756 could up-regulate MMP-1 expression in the presence of
an even higher concentration of IL-1RA (1.0 g/ml) (Fig. 2B),
which is the concentration used by other groups for blocking
the IL-1 autocrine loop in dermal fibroblasts (33, 34). Taken
together, the results show that the IL-1 autocrine loop is an
essential pathway for A3G756-mediated induction of MMP-1 in
keratinocytes, but it is not necessary in fibroblasts, even
though A3G756 was able to induce IL-1 gene expression (Fig.
1D) and exogenously added IL-1 increased MMP-1 gene ex-
pression (Fig. 1C).
Increase of MMP-1 Protein Levels by A3G756—Increase of
the MMP-1 protein by A3G756 in the keratinocytes was dem-
onstrated by Western blotting of the conditioned medium.
MMP-1 protein levels increased in the 12–33-h incubations, but
not in the 6- and 8-h incubation, whereas protein levels of IL-1
increased within the 6–12-h incubation (Fig. 3A). Although
IL-1 showed rather rapid disappearance from the conditioned
medium, the observation that IL-1 expression preceded the
MMP-1 expression were consistent with the facts that newly
synthesized IL-1 induced MMP-1 expression in the keratino-
cytes. The increase of basal expression of MMP-1 at 33-h incu-
FIG. 1. MMP-1 gene expression induced by recombinant 3 LG4 and synthetic peptide A3G756. Recombinant 3 LG4, A3G756, or IL-1
was incubated with keratinocytes and fibroblasts. RNA was prepared at 8-h incubation. Semi-quantitative RT-PCR products were separated on
a 1.5% agarose gel and visualized by ethidium bromide staining. A, RT-PCR of MMP-1 in keratinocytes. Lane 1, control scrambled peptide S4; lane
2, A3G756; lanes 3 and 4, recombinant 3 LG4; lane 5, A3G756 with heparin (30 g/ml); lane 6, recombinant 3 LG4 with heparin (30 g/ml). B,
pooled results of RT-PCR analysis. The scanned results were calculated by NIH Image 1.60 and relative mRNA values are shown as the ratio of
MMP-1 intensity to that of GAPDH. Data presented are mean  S.D. of three independent experiments. C, RT-PCR of IL-1 was performed using
keratinocytes or fibroblasts incubated with 24 g/ml A3G756 or S4. D, the effect of IL-1 (10 units/ml) on MMP-1 gene expression in keratinocytes
and fibroblasts. E, keratinocytes were incubated with 24 g/ml A3G756 or S4 in the presence or absence of 2.0 g/ml cycloheximide (CHX).
Representative data are shown in three independent RT-PCR experiments in C–E.
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bation without peptide stimulation likely represents the accu-
mulation of MMP-1 protein as also seen in the fibroblasts (Fig.
3C). These data confirm that up-regulation of MMP-1 mRA
levels by A3G756 results in increased protein levels. MMP-1
protein levels in fibroblasts were also examined by ELISA
using the conditioned medium. A dose-dependent increase in
MMP-1 protein levels was observed by incubation of fibroblasts
with various amounts of A3G756 in a 24-h incubation (Fig. 3B).
The MMP-1 protein level reached plateau at 24 g/ml A3G756.
Within the 8-h incubation, protein levels of MMP-1 did not
FIG. 2. IL-1 receptor antagonist inhibits A3G756-mediated MMP-1 induction in keratinocytes but not in fibroblasts. Keratinocytes
(A) or fibroblasts (B) were incubated for 8 h with S4 or A3G756 peptide (24 g/ml) with or without heparin (Hep) (30 g/ml) or IL-1 receptor
antagonist (IL-1RA) (0.3 g/ml for keratinocytes and 1.0 g/ml for fibroblasts). Upper, RT-PCR products were analyzed on an agarose gel and
visualized by ethidium bromide staining. Lower, pooled results of RT-PCR. The scanned results of the gels were calculated by NIH Image 1.60, and
relative mRNA values are shown as the ratio of MMP-1 intensity to that of GAPDH. Data presented are mean  S.D. of four independent
experiments.
FIG. 3. A3G756 increases MMP-1 in the conditioned medium of keratinocytes (A) and fibroblasts (B–D). A, Western blotting analysis
of MMP-1 and IL-1 in keratinocyte conditioned medium. Keratinocytes were incubated with 24 g/ml A3G756 for 6, 8, 12, 24, and 33 h.
Conditioned media were collected and lyophilized. The samples were analyzed by Western blotting. Anti-MMP-1 antibody detects a 55-kDa species.
Anti-IL-1 antibody reveals a 31-kDa species when the same membrane was used after stripping. Similar expression patterns were observed in
two independent experiments. B, dose-dependent MMP-1 induction. Fibroblasts were incubated with various amounts of peptides for 24 h. C, time
course of MMP-1 induction. Fibroblasts were incubated with 24 g/ml peptides for indicated periods. D, fibroblasts were treated with peptides (24
g/ml) or IL-1 (10 units/ml) for 24 h with or without heparin (30 g/ml) or IL-1RA (1.0 g/ml). MMP-1 in the conditioned medium was measured
by ELISA. Data presented are mean  S.D. and are representative results of three independent experiments.
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change significantly, but after 16 h of incubation, it increased
and the reached its maximum level by 24 h (Fig. 3C). AG756-
mediated induction of MMP-1 protein was inhibited by heparin
but not by IL-1 receptor antagonist in fibroblasts (Fig. 3D).
Exogenous IL-1 induced MMP-1 expression in fibroblasts
(Fig. 3D), and IL-1 receptor antagonist blocked the IL-1-me-
diated induction (data not shown). The failure of the IL-1
receptor antagonist to inhibit A3G756-mediated MMP-1 induc-
tion in fibroblasts suggests that IL-1 is not necessary for
MMP-1 induction, although exogenous IL-1 induced MMP-1
expression. These results were consistent with those of mRNA
changes in fibroblasts.
A3G756 Activates MAPK Signaling—Because IL-1 is
known to activate MAPKs, activation of MAPKs was analyzed
by Western blotting with anti-phosphorylated MAPK antibod-
ies (Fig. 4). Treatment of keratinocytes with recombinant 3
LG4 or A3G756 activated p38 MAPK (Fig. 4A). Activation of
p38 MAPK by A3G756 was observed after 15 min of incubation
and reached the maximum level at 2 h. A3G756 also activated
Erk within 6 h of incubation (Fig. 4B). During these incubation
periods, c-Jun N-terminal kinase was not activated (data not
shown). As expected, exogenous IL-1 activated both p38
MAPK and Erk in keratinocytes at 15-min incubation (Fig. 4A,
4B). Activations of p38 MAPK and Erk by A3G756 were com-
pletely blocked by the addition of heparin (Fig. 4, A and B).
These results indicate that A3G756 induces rapid activation of
p38 MAPK and slow activation of Erk in keratinocytes. The
activation of Erk was drastically inhibited by the addition of
IL-1 receptor antagonist, but p38 MAPK activation was par-
tially blocked (Fig. 4C). These findings suggest that the Erk
activation observed at 6-h incubation was predominantly me-
diated by the IL-1 autocrine loop. Although at least a part of
p38 MAPK activation at 6-h incubation with A3G756 was me-
diated by the IL-1 autocrine loop, there should be another
pathway, e.g. a direct activation of p38 MAPK.
In fibroblasts, p38 MAPK was phosphorylated at 15-min
incubation and returned to a basal level after 1-h incubation
with A3G756 (Fig. 4D). Erk activation was not detectable from
15 min to 6 h of incubation, and p38 MAPK was not activated
from 2 to 6 h of incubation (data not shown). These different
profiles of MAPK activation indicate that A3G756-syndecan
binding transduces signals in a cell type-specific manner.
The Effects of MAPK Inhibitors on A3G756 Induction of
MMP-1 or IL-1—Because A3G756 activated p38 MAPK
and/or Erk, we examined whether MAPK inhibitors block the
up-regulation of MMP-1 by A3G756. RT-PCR analysis showed
that SB202190, a specific inhibitor of p38 MAPK, blocked the
up-regulation of MMP-1 and IL-1 in keratinocytes (Fig. 5A).
PD98059, an inhibitor of Erk, blocked the up-regulation of
MMP-1, but did not change the IL-1 induction (Fig. 5A).
Together with the observation that Erk activation was inhib-
ited by IL-1 receptor antagonist, these results indicate that Erk
is involved in the up-regulation of MMP-1 through the IL-1
autocrine loop in keratinocytes.
In fibroblasts, PD98059 inhibited both MMP-1 and IL-1
mRNA induction, whereas SB202190 inhibited only IL-1
mRNA induction (Fig. 5B). There are two differences in the
responses to MAPK inhibitors. One is that both p38 MAPK and
Erk activation are required for IL-1 mRNA induction. The
other is that blockade of IL-1 mRNA induction by SB202190
did not abolish the MMP-1 induction. These results suggest
that IL-1 is not involved in A3G756-mediated MMP-1 induc-
FIG. 4. MAPK activation by A3G756 in keratinocytes (A–C) and fibroblasts (D). Keratinocytes were treated with 3 LG4 (15 g/ml), S4
(24 g/ml), A3G756 (24 g/ml), or IL-1 (10 units/ml) for 15 min to 6 h. Cell lysates were prepared and analyzed by Western blotting. A, a
membrane was first probed with anti-phosphorylated p38 antibody (P-p38) and then successively with anti-p38 antibody after stripping (p38). The
ratio of the intensity of phosphorylated p38 to that of p38 (P-p38/p38) was determined using NIH image 1.60, and the ratio of the sample with no
stimulation or with control peptide S4 was taken as 1.0. Representative results are shown for three independent experiments. The p38
phosphorylation at 2-h incubation was blocked by the addition of heparin (100 g/ml) into the medium during incubation. The cells were
preincubated with heparin for 15 min before peptide stimulation. Keratinocytes were also examined by Western blotting with anti-phosphorylated
Erk (P-Erk) and then successively with anti-Erk antibody after stripping (Erk). A3G756 activated Erk at 6-h incubation, and this activation was
blocked by the addition of heparin. C, keratinocytes were incubated with A3G756 or S4 for 6 h in the presence or absence of IL-1RA (0.3 g/ml),
and cell lysates were subjected to Western blotting. D, fibroblasts were incubated with S4 or A3G756 for 15 min and 1 h. Similar results were
obtained in three independent experiments in B–D.
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tion in fibroblasts. Similar patterns were obtained in MMP-1
protein levels estimated by ELISA in fibroblasts (Fig 5C).
PD98059, but not SB202190, completely blocked the increase of
MMP-1 protein levels by A3G756. Only Erk activation is nec-
essary for A3G756-mediated MMP-1, although Erk activation
could not be demonstrated in fibroblasts by Western blotting as
mentioned (Fig. 4D).
Colocalization of 3 LG4 and Syndecans—Previously we
showed that 3 LG4 and A3G756 bind keratinocytes and fibro-
blasts through syndecans in solid phase binding assays (12).
Here we demonstrate that soluble 3 LG4 is colocalized with
syndecans on the cell surface of dermal fibroblasts (Fig. 6). For
this experiment, we obtained dermal fibroblast cell lines that
were stably transfected with the expression vector for synde-
can-2 or syndecan-4. Incubation of syndecan-expressing fibro-
blasts with 3 LG4 showed colocalization of 3 LG4 with syn-
decan-2 or syndecan-4 in double immunostaining (Fig. 6). The
3 LG4 binding was completely diminished by the addition of
heparin (30 g/ml) in both clones during the incubation (data
not shown). These results confirm that 3 LG4 interacts with
syndecans on the cell surface.
DISCUSSION
In this report, we found that the 3 LG4 module of laminin-5
induces MMP-1 expression by activating the MAPK signaling
pathway. We also found that this process involves the IL-1
autocrine loop in keratinocytes. The 3 LG4-mediated induc-
tion of MMP-1 occurs through the interaction of syndecans with
the A3G756 sequence within the module. Therefore, we are
interested in the structure of the 3 LG4 module and the
location of the active A3G756 site within the module structure.
Although the structure of the LG4–5 module of laminin 3 is
not known, the crystal structure of the LG4–5 domain pair of
laminin 2 was reported (30). Fig. 7 shows the structure-se-
quence-based alignment of human 3 LG4–5 generated using
the murine 2 LG4–5 structure as a template. The basic resi-
dues, Lys (Lys-1421) and Arg (Arg-1423), critical for syndecan
binding (12) are exposed and clustered within the sequence of
A3G756 (residues 1411–1429; KNSFMALYLSKGRLVFALG)
within the LG4 module, which consists of 14  strands forming
a -sheet sandwich. These two residues are located at one end
of a cleft formed by the loop connecting  strands. This cleft
contains several further surface-exposed basic residues that
might provide a specific orientation to the extended glycosami-
noglycan chains by interaction with their sulfate groups. This
would be consistent with the active bases of 2 LG4–5 for
-dystroglycan and heparin binding. These results suggest that
the A3G756 site of laminin 3 is exposed on the surface of the
3 LG4 structure and is active for syndecan binding.
It has been reported that exogenous IL-1 activates p38
MAPK and leads to up-regulation of MMP-1 expression in
fibroblasts (31, 32). Inhibitor of p38 MAPK blocked A3G756-
mediated IL-1 expression in keratinocytes (Fig. 5). However,
IL-1 receptor antagonist could not completely inhibit p38
MAPK activation in keratinocytes (Fig. 4C). Therefore, p38
MAPK is likely involved in both pathways, one from syndecan
to IL-1 up-regulation and the other from IL-1 receptor to
MMP-1 up-regulation. Erk activation was detected as early as
6 h after incubation with keratinocytes. The activation of Erk
was drastically inhibited by the addition of IL-1 receptor an-
tagonist. Further, PD98059, an inhibitor of Erk, did not block
FIG. 5. The effects of MAPK inhibitors on A3G756-mediated MMP-1 or IL-1 induction. Keratinocytes (A) or fibroblasts (B and C) were
incubated with 24 g/ml S4 or A3G756 in the presence of PD98059 (20 g/ml) (PD) or SB202190 (30 g/ml) (SB) for 8 h, and then RNA was
prepared. A, electrophoresis of RT-PCR products and pooled data of RT-PCR are shown. Scanned results were calculated by NIH Image 1.60. The
relative values are shown as the ratio of the intensity of MMP-1 or IL-1 to that of GAPDH. Data presented are mean  S.D. of five independent
experiments in A and B. B, pooled data of RT-PCR in fibroblasts. C, the fibroblast culture medium was collected after 24-h incubation with peptides
in the presence or absence of PD98059 or SB202190 and analyzed by ELISA. Data are mean  S.D. of three independent experiments.
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A3G756-mediated IL-1 induction in keratinocytes. Therefore,
it is likely that Erk mediates signaling from IL-1 receptor to
MMP-1 gene expression. Because Erk activation by exogenous
IL-1 in keratinocytes is mediated by epidermal growth factor
receptor transactivation (35), Erk activation via the syndecan-
IL-1 pathway may be induced by a similar mechanism.
We showed that exogenous IL-1 stimulated MMP-1 gene
expression and that A3G756 up-regulated IL-1 gene expres-
sion in fibroblasts (Fig. 1). Therefore, the involvement of the
IL-1 autocrine loop in A3G756-mediated induction of MMP-1
in fibroblasts is possible. However, in fibroblasts, IL-1 auto-
crine loop and MMP-1 up-regulation likely occur by an inde-
pendent mechanism. Unlike keratinocytes, p38 MAPK activa-
tion was not needed for A3G756-mediated induction of MMP-1
in fibroblasts (Fig. 5B). It was reported that, in fibroblasts,
basic fibroblast growth factor-mediated induction of MMP-1
required activation of Erk, but not p38 MAPK (32). Signaling
from syndecan may up-regulate and/or activate another fac-
tor(s) for MMP-1 up-regulation through Erk, independent of
the IL-1 autocrine pathway in fibroblasts.
There are four mammalian syndecans, all of which are trans-
membrane heparan sulfate proteoglycans. Syndecans bind to
extracellular matrices as a cell surface receptor and store fi-
broblast growth factors and vascular endothelial growth factors
(for review, see Refs. 36 and 37). Syndecan-1 is the major
syndecan of epithelial cells, syndecan-2 is that of mesenchymal
cells, and syndecan-3 is that of neural tissues. Syndecan-4 is
widely distributed. Usually, more than one syndecan are ex-
pressed in a single cell type. The carboxyl terminus of a short
cytoplasmic module is conserved in the syndecan family and
can interact with syndecan type-specific PDZ-domain-contain-
ing proteins. With these signal-transducing molecules, synde-
cans may have unique functions other than cell adhesion. It is
conceivable that a different set of syndecan isoforms expressed
at the cell surface of keratinocytes (syndecan-1 and -4) and
fibroblasts (syndecan-2 and -4) may play a key role in regulat-
ing different responses to laminin 3 LG4. Activating antibody
to 51 integrin increases MMP-1 gene expression via the IL-1
autocrine loop in fibroblasts (38). Recently, it was reported that
the signal from syndecan-4, but not from syndecan-2, transac-
tivates integrin 1 (39). Taken all together, these results sug-
gest that signals from syndecan binding to laminin 3 LG4 may
activate integrins, resulting in MMP-1 induction.
Keratinocytes are known to produce MMPs when they con-
tact collagen fibers at a wound site. MMP-1 degrades collagen
I, allowing keratinocytes to migrate on the wound granulation
tissue under desiccated eschar. It is also possible that syndecan
binding to laminin 3 LG4 contributes to re-epithelization with
two different activities such as cell adhesion and MMP-1 in-
duction. The identification of the precise mechanisms of how
syndecan binding to laminin 3 LG4 can induce MMP-1 gene
expression may lead to the development of clinical applications
for wound healing.
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